• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The TRACT trial: no mortality benefit observed in African children with uncomplicated severe anemia who receive transfusion

byDayton McMillan
August 2, 2019
in Chronic Disease, Emergency, Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In African children with uncomplicated severe anemia, immediate blood transfusion did not notably alter patient mortality at 1- or 6-months post treatment compared to patients treated under current practice.

2. Rates of hospital readmission, serious adverse events, and hemoglobin recovery were similar between the two groups.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Severe anemia, with hemoglobin <6 g/dl, is a leading cause of hospitalization in African children. Patients admitted for severe anemia have notable mortality rates. Due to resource limitations, transfusion for uncomplicated severe anemia is not advised if hemoglobin is between 4 and 6 g/dl. This randomized controlled trial evaluated patients who received immediate transfusion and those who did not, with no mortality difference observed between the two groups at 1 month or 6 months post randomization. Additionally, secondary outcomes of readmission, serious adverse events, and hemoglobin recovery at 6 months did not differ between the groups.

This study clinically evaluates patient outcomes observed for patients treated with notably different treatment thresholds, and secondarily evaluates resource utilization for context. Of note, hospital stay was longer for the control group and cost implications of monitoring are a consideration despite there being no observed mortality benefit to immediate transfusion.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis – the ASCEND-ID trial

Relevant Reading: Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial

In-Depth [randomized controlled trial]: This multicenter, factorial, randomized, controlled trial enrolled patients in Uganda and Malawi between 2014 and 2017. Eligible patients were between 2 months and 12 years of age and were hospitalized for uncomplicated severe anemia with a hemoglobin between 4 and 6 g/dl. Patients with known chronic diseases (including sickle cell disease) or who were admitted for an acute illness were excluded. Patients were randomly assigned in a 1:1 manner to undergo immediate transfusion (n=778) or no immediate transfusion (n=787), with transfused patients receiving 20 or 30 ml of whole blood per kilogram of body weight. Patients were monitored while in the hospital and at days 28, 90, and 180 post discharge for clinical outcomes and hemoglobin levels. The primary outcome of mortality at 28 days post-randomization occurred in 0.9% and 1.7% of patients in the treatment and controls groups, respectfully (hazard ratio, 0.54; 95% confidence interval [CI], 0.22 to 1.36; P=0.19). At day 180 mortality had occurred in 4.5% and 6.0% of treatment and control patients, respectfully (hazard ratio, 0.75; 95% CI, 0.48 to 1.15). By day 28 hemoglobin level was higher in the treatment group by an average of 0.6 g/dl, though by day 180 there was no significant difference in hemoglobin levels between groups. The median length of stay was 3 days in the treatment group and 4 days in the control group. The costs of treatment, including for hospital stay, transfusions, and blood tests, was $72.09 in the immediate-transfusion group and $66.46 in the control group. Over a period of 180 days, life-years gained was similar in the two groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: \Africaanemiablood transfusionMalawiUganda
Previous Post

2 Minute Medicine Rewind July 15, 2019

Next Post

Quick Take: Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

RelatedReports

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

April 14, 2022
Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis – the ASCEND-ID trial

April 8, 2022
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

March 16, 2022
Next Post
Adding daratumumab increases progression free survival in multiple myeloma

Quick Take: Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

#VisualAbstract: Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease

#VisualAbstract: Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease

The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax

Survival increased in chronic lymphocytic leukemia patients treated with ibrutinib and rituximab

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
  • Several factors influence health programs conducted in the African American Church
  • Imiquimod noninferior to surgery in management of vulvar high-grade squamous intraepithelial lesions
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.